Cargando…
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
BACKGROUND: Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA). However, few studies on the efficacy of this biologic in...
Autores principales: | Numata, Takanori, Miyagawa, Hanae, Nishioka, Saiko, Okuda, Keitaro, Utsumi, Hirofumi, Hashimoto, Mitsuo, Minagawa, Shunsuke, Ishikawa, Takeo, Hara, Hiromichi, Araya, Jun, Kuwano, Kazuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398222/ https://www.ncbi.nlm.nih.gov/pubmed/32746787 http://dx.doi.org/10.1186/s12890-020-01248-x |
Ejemplares similares
-
Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2022) -
Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2021) -
Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2022) -
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019) -
Possible relationship between esophageal dilatation and severity of M. abscessus pulmonary disease
por: Hara, Hiromichi, et al.
Publicado: (2021)